Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Medical-imaging technology company Polarean Imaging posted a first-half loss, as revenue fell and it invested in clinical trails.
Pre-tax losses for the six months through June amounted to $3.4m, compared to losses of $2.8m on-year.
Revenue fell to to $0.4m, down from $1.0m, which the company said was mostly due to the timing of polariser sales.
'We continue to demonstrate and reinforce our belief that Polarean's technology can be a tremendous benefit to patients and a powerful new tool for clinicians in discovering and demonstrating treatable traits in pulmonary medicine,' chief executive Richard Hullihen said.
'In addition, our latest new techniques lead us into the field of cardiology and pulmonary vascular disease which is one example of the upside potential of our technology.'
'We believe that our unique medical drug-device combination utilizing 129Xe offers the ideal solution for improving pulmonary disease diagnosis and we are confident that this will be borne out during the company's clinical trials.'
At 2:35pm: (LON:POLX) Polarean Imaging Plc Ord Gbp0.00037 share price was -0.7p at 18.3p